Genome Editing Core
Genome Editing Core
批准号:
9921399
负责人:
Stephan Kissler
金额:
$22.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AllelesAnimal ModelAreaBiological ModelsBlood specimenCRISPR/Cas technologyCell LineCell LineageCell modelCellsClinicalCollaborationsCollectionCommunitiesComplementConsultationsCustomDNADatabasesDefectDepositionDevelopmentDiabetes MellitusDiseaseDisease modelElementsEmbryoEngineeringEpigenetic ProcessExperimental DesignsExperimental ModelsFibroblastsGene DeletionGene Transfer TechniquesGenerationsGenesGeneticGenetic HeterogeneityGenetic studyGenomeGuide RNAHumanIn VitroIndividualInsulin-Dependent Diabetes MellitusKnock-inKnock-outLaboratory miceLinkMediatingMedical GeneticsMessenger RNAMethodologyMethodsMicroinjectionsModelingModificationMolecularMusNon-Insulin-Dependent Diabetes MellitusPathologyPathway interactionsPatientsPhenotypePluripotent Stem CellsProductionRNA InterferenceReagentResearchResearch PersonnelResourcesSamplingServicesSomatic CellSourceSpeedStandardizationSumSystemTechniquesTestingTimeTrainingTransgenesTranslational ResearchUpdateValidationbasebiobankcell typeclinical heterogeneitycohortcost effectivedesigndiabeticdiabetic patientexperimental studyfunctional genomicsgene replacementgenetic variantgenome editinghuman diseasehuman modelin vivoin vivo evaluationinduced pluripotent stem cellinterestknock-downmaturity onset diabetes of the youngmouse modelnovelnovel therapeuticsnuclear reprogrammingpatient populationperipheral bloodpre-clinicalrepositoryresponsestemstem cell technologytooltranscription factorzygote
中文摘要
核心5 -基因组编辑核心:摘要
英文摘要
CORE 5 - GENOME EDITING CORE: ABSTRACT
Investigating mechanisms that underlie diabetes and its complications requires relevant experimental models.
In recent years, induced pluripotent stem (iPS) cells have provided a unique means to study disease-relevant
molecular pathways in patient-specific cells. The development of genome editing tools such as the CRISPR-
Cas9 system has made it possible to accurately engineer cells and further refine disease modeling using iPS
cells. Studies of iPS-derived cells are invaluable to the modeling of human cellular defects. However, cell-
based experiments do not adequately reflect systemic changes associated with diabetes. Animal models are
equally important and necessary to complement in vitro experimentation. Genome editing techniques have
also made it possible to very quickly and efficiently generate new diabetes-relevant mouse models to
interrogate mechanisms of disease.
The Genome Editing Core (GEC) will provide a platform for investigators to create novel and unique human
cellular models and mouse models to study diabetes and its complications. The GEC will use state-of-the-art
methodology to 1) generate patient-specific iPS cell lines, 2) edit the genome of iPS and iPS-derived cells to
probe individual genes or gene variants and 3) generate custom mouse models by gene knockdown, knock-in,
knock-out or replacement. In addition to providing these services, the GEC will offer advice, reagents and tools
for genome editing of experimental models and offer training for the generation and manipulation of iPS cell
lines. In collaboration with the newly proposed Clinical Translational Research Core, the GEC will also serve
as a repository for a large collection of unique iPS cell lines derived from type 1 diabetes, type 2 diabetes and
MODY patients sourced from Joslin's extensive patient population. In sum, the GEC will constitute an
invaluable resource for all aspects of diabetes research by facilitating the custom generation of relevant model
systems.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening
-
批准号:10209642
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2018
-
负责人:Stephan Kissler
-
依托单位:
Genome Editing Core
-
批准号:10160880
-
项目类别:
-
资助金额:$22.09万
-
财政年份:1997
-
负责人:Stephan Kissler
-
依托单位:
海外基金